Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/175395
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Saavedra, Ana | - |
dc.contributor.author | Alberch i Vié, Jordi, 1959- | - |
dc.contributor.author | Pérez Navarro, Esther | - |
dc.date.accessioned | 2021-03-19T11:24:09Z | - |
dc.date.available | 2021-03-19T11:24:09Z | - |
dc.date.issued | 2012-02-15 | - |
dc.identifier.uri | http://hdl.handle.net/2445/175395 | - |
dc.description.abstract | The molecular bases that account for the preferential neurodegeneration of striatal mediumsized spiny neurons (MSNs) in Huntington’s Disease (HD) are still unknown, and different mechanisms have been proposed to contribute to the neurodegenerative process. These include mitochondrial dysfunction and metabolic impairment, transcriptional dysregulation, altered expression of trophic factors, dopamine toxicity, oxidative stress, and changes in autophagy, and huntingtin (htt) phosphorylation. In addition, excitotoxicity through the overactivation of N-methyl-D-aspartate (NMDA) receptors (NMDARs) has also been proposed to contribute to the preferential loss of these neurons (for review see Ehrnhoefer et al., 2011; Jin & Johnson, 2010; Perez-Navarro et al., 2006; Renna et al., 2010; Rosenstock et al., 2010; Weir et al., 2011). Some of these mechanisms are controlled by the attachment/removal of phosphate groups through the action of protein kinases and protein phosphatases, respectively. Therefore, alterations in their levels/activity in the presence of mutant htt (mhtt) can impact on cell survival... | ca |
dc.format.extent | 30 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | ca |
dc.publisher | IntechOpen | ca |
dc.relation.isformatof | Reprodució del document publicat a: http://doi.org/10.5772/30850 | - |
dc.relation.ispartof | Chapter 20 in: Ersoy Tunali, Nagehan. 2012. Huntington's Disease: Core Concepts and Current Advances. IntechOpen. ISBN: 978-953-51-4359-8. DOI: 10.5772/1470. pp: 465-494. | - |
dc.relation.uri | http://doi.org/10.5772/30850 | - |
dc.rights | cc by (c) Saavedra, Ana et al., 2012 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Llibres / Capítols de llibre (Biomedicina) | - |
dc.subject.classification | Corea de Huntington | cat |
dc.subject.classification | Fosfatases | cat |
dc.subject.classification | Medicina clínica | - |
dc.subject.other | Huntington's chorea | eng |
dc.subject.other | Phosphatases | eng |
dc.subject.other | Clinical medicine | - |
dc.title | Don’t Take Away My P: Phosphatases as Therapeutic Targets in Huntington’s Disease | ca |
dc.type | info:eu-repo/semantics/bookPart | ca |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 275161 | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | ca |
Appears in Collections: | Llibres / Capítols de llibre (Biomedicina) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
275161.pdf | 736 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License